2,5-Dichloropyrimidine-4-carboxylic acid | 1240594-41-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 2,5-Dichloropyrimidine-4-carboxylic acid
• CAS: 1240594-41-5
• 化学式: C₅H₂Cl₂N₂O₂
• mdl: MFCD16988028
• 分子量: 192.98
• InChiKey: OSDYPLYOFIWZEU-UHFFFAOYSA-N

物化性质

• 沸点：
  422.8±25.0 °C(Predicted)
• 密度：
  1.718±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  63.1
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• [EN] PHARMACEUTICAL COMPOUNDS<br/>[FR] COMPOSÉS PHARMACEUTIQUES
  申请人：ALMAC DISCOVERY LTD

  公开号：WO2015019037A1

  公开（公告）日：2015-02-12

  The present invention relates to compounds that are useful as inhibitors of the activity of Wee-1 kinase. The present invention also relates to pharmaceutical compositions comprising these compounds and to methods of using these compounds in the treatment of cancer and methods of treating cancer.

  本发明涉及一种作为Wee-1激酶活性抑制剂有用的化合物。本发明还涉及包含这些化合物的药物组合物，以及在癌症治疗中使用这些化合物的方法和治疗癌症的方法。
• [EN] HETEROCYCLIC COMPOUNDS USEFUL AS HPK1 INHIBITORS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES UTILES EN TANT QU'INHIBITEURS DE HPK1
  申请人：SILEXON BIOTECH CO LTD

  公开号：WO2022253252A1

  公开（公告）日：2022-12-08

  Disclosed herein are compounds of Formula (I) : or pharmaceutically acceptable salts thereof. Also disclosed are methods of using such compounds to modulate or inhibit the enzymatic activity of hematopoietic progenitor kinase (HPK1), and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of ΗΡK1-associateddiseases or disorders, e.g. viral infections and cancers.

  本文揭示了以下式（I）的化合物或其药学上可接受的盐。还揭示了使用这些化合物来调节或抑制造血祖细胞激酶（HPK1）的酶活性的方法，以及包含这些化合物的制药组合物。这些化合物在治疗与HPK1相关的疾病或疾病中有用，例如病毒感染和癌症。
• USEFUL COMBINATIONS OF MONOBACTAM ANTIBIOTICS WITH BETA-LACTAMASE INHIBITORS
  申请人：Basilea Pharmaceutica AG

  公开号：EP1965798A2

  公开（公告）日：2008-09-10
• [EN] USEFUL COMBINATIONS OF MONOBACTAM ANTIBIOTICS WITH BETA-LACTAMASE INHIBITORS<br/>[FR] ASSOCIATIONS UTILES D'ANTIBIOTIQUES MONOBACTAMES ET D'INHIBITEURS DE LA BETA-LACTAMASE
  申请人：BASILEA PHARMACEUTICA AG

  公开号：WO2007065288A2

  公开（公告）日：2007-06-14

  (EN) A pharmaceutical composition, comprising a combination of an antibiotically active compound of the formula (I): with a ß-lactamase inhibitor of one of the formulae (II) to (XIII) are active against Gram-negative bacteria, in particular such bacteria which have become resistant against antibiotics such as aztreonam, carumonam and tigemonam. Optionally the compositions may comprise another ß-lactamase inhibitor of one of the formulae (II) to (XIII), particularly of formula (V) or formula (VI).(FR) La présente invention concerne une composition pharmaceutique comprenant une association d'un composé présentant une activité antibiotique répondant à la formule (I): et d'un inhibiteur de la ß-lactamase répondant à l'une des formules (II) à (XIII), qui sont actifs contre les bactéries Gram-négatives, en particulier contre les bactéries devenues résistantes aux antibiotiques tels que l'aztréonam, le carumonam et le tigémonam. En option, ces préparations peuvent contenir un autre inhibiteur de la ß-lactamase répondant à l'une des formules (II) à (XIII), en particulier à la formule (V) ou à la formule (VI).
• [EN] SUBSTITUTED PYRIMIDINES AS INHIBITORS OF HIF PROLYL HYDROXYLASE<br/>[FR] PYRIMIDINES SUBSTITUÉES UTILISÉES COMME INHIBITEURS DE LA HIF PROLYL HYDROXYLASE
  申请人：MERCK SHARP & DOHME

  公开号：WO2016054804A1

  公开（公告）日：2016-04-14

  The present invention concerns compounds of Formula I that inhibit HIF prolyl hydroxylase, their use for enhancing endogenous production of erythropoietin, and for treating conditions associated with reduced endogenous production of erythropoietin such as anemia and like conditions, as well as pharmaceutical compositions comprising such a compound and a pharmaceutical carrier.